Sarepta Therapeutics(US:SRPT) Prnewswireยท2025-07-11 13:00Core Viewpoint - A class action securities lawsuit has been filed against Sarepta Therapeutics, Inc. due to alleged securities fraud affecting investors between June 22, 2023, and June 24, 2025 [1] Group 1: Lawsuit Details - The complaint alleges that Sarepta made false statements regarding the safety of its gene therapy ELEVIDYS for Duchenne, claiming it posed significant safety risks to patients [2] - It is claimed that the trial protocols for ELEVIDYS failed to detect severe side effects, leading to potential halting of recruitment and dosing in trials, attracting regulatory scrutiny [2] - The lawsuit asserts that the severity of adverse events from ELEVIDYS treatment misled investors and lacked a reasonable basis for positive statements made by the company [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]